Literature DB >> 30714525

The Clinical Prognostic Value of LRG1 in Esophageal Squamous Cell Carcinoma.

Yuanyuan Wang1,2, Qian Xing2, Xue Chen1, Jianbo Wang1, Shanghui Guan1, Xuan Chen1, Peng Sun3, Mingxia Wang4, Yufeng Cheng1.   

Abstract

BACKGROUND: Leucine-rich-alpha-2-glycoprotein1 (LRG1) is a new oncogene-related gene, which has been proven important for the development and poor prognosis of human cancers. However, whether it participates in esophageal squamous cell carcinoma (ESCC) progression remains unclear.
OBJECTIVE: To investigate the expression level and functional influence of LRG1 in ESCC.
METHODS: The expression of LRG1 was evaluated on the mRNA and protein level in ESCC patients. Then, correlation of LRG1 expression with clinicpathological variables was analyzed in ESCC. Besides, to clarify the biological function of LRG1, Eca109 and KYSE150 cells were transfected with LRG1 shRNA, the cell viability, clonal efficiency, apoptosis and invasion assays in vitro were performed.
RESULTS: LRG1 was significantly over-expressed in ESCC and related to deeper invasion depth (T stage) and distal metastasis (M stage). Kaplan-Meier analysis indicated that LRG1 up-regulation in ESCC was closely correlated to worse clinical survival (overall survival and progression-free survival), all P<0.001. LRG1 was confirmed to be an independent poor premonitory indicator for clinical outcomes in ESCC through the univariate and multivariate analyses. Down-regulation of LRG1 in ESCC cells markedly suppressed cell proliferation and invasion, stimulated apoptosis (all p <0.01).
CONCLUSION: LRG1 might play a significant role in the progression of ESCC, and could be served as a promising prognostic prediction for ESCC patients. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  LRG1; esophageal carcinoma; invasion; prognosis; proliferation; squamous cell carcinoma.

Mesh:

Substances:

Year:  2019        PMID: 30714525     DOI: 10.2174/1568009619666190204095942

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  7 in total

Review 1.  The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors.

Authors:  Meng Lin; Jinmeng Liu; Fengping Zhang; Gaoxiu Qi; Shuqi Tao; Wenyuan Fan; Min Chen; Kang Ding; Fenghua Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-17       Impact factor: 4.553

2.  LRG1 in pancreatic cancer cells promotes inflammatory factor synthesis and the angiogenesis of HUVECs by activating VEGFR signaling.

Authors:  Duxiong Cai; Chunji Chen; Yexiong Su; Yan Tan; Xuyue Lin; Rong Xing
Journal:  J Gastrointest Oncol       Date:  2022-02

Review 3.  Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review.

Authors:  Yonghui Zou; Yi Xu; Xiaofeng Chen; Yaoqi Wu; Longsheng Fu; Yanni Lv
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

4.  Cross-platform validation of a mouse blood gene signature for quantitative reconstruction of radiation dose.

Authors:  Shanaz A Ghandhi; Igor Shuryak; Brian Ponnaiya; Xuefeng Wu; Guy Garty; Shad R Morton; Salan P Kaur; Sally A Amundson
Journal:  Sci Rep       Date:  2022-08-19       Impact factor: 4.996

5.  Identification of candidate aberrantly methylated and differentially expressed genes in Esophageal squamous cell carcinoma.

Authors:  Bao-Ai Han; Xiu-Ping Yang; Davood K Hosseini; Po Zhang; Ya Zhang; Jin-Tao Yu; Shan Chen; Fan Zhang; Tao Zhou; Hai-Ying Sun
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379

6.  MicroRNA-497 elevation or LRG1 knockdown promotes osteoblast proliferation and collagen synthesis in osteoporosis via TGF-β1/Smads signalling pathway.

Authors:  ZhengTao Gu; DengHui Xie; CaiQiang Huang; Rui Ding; RongKai Zhang; QingChu Li; ChuangXin Lin; YiYan Qiu
Journal:  J Cell Mol Med       Date:  2020-09-24       Impact factor: 5.310

Review 7.  LRG1: an emerging player in disease pathogenesis.

Authors:  Carlotta Camilli; Alexandra E Hoeh; Giulia De Rossi; Stephen E Moss; John Greenwood
Journal:  J Biomed Sci       Date:  2022-01-21       Impact factor: 12.771

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.